BCMA CAR mRNA

BCMA CAR mRNA (N1-Me-Pseudo UTP) expresses anti-BCMA chimeric antigen receptor (CAR) in cells or in vivo. B-cell maturation antigen(BCMA or BCM) is a common biomarker for multiple myeloma. This CAR mRNA can be used in oncology research and cell therapy development. CAR mRNA is prepared at higher concentration, convenient for immune cell electroporation and LNP formulation.

This mRNA features following structure: 

• Cap 1 (N7-methylguanosine Cap) with high capping efficiency 
• Poly(A) tail with 100 consecutive A 
• 5’ and 3’ UTR with proven efficient translation 
• ORF with codon optimization
• N1-methyl-pseudouridine modification

Competitive advantage of AmRNA product:

At AmRNA, we are committed to delivering ready-to-use mRNA of the highest quality standards (only A grade). Each mRNA is produced using state-of-the-art industrial synthesis and purification technologies, ensuring ultra-high purity, capping efficiency, and poly(A) tail integrity. Residual impurities such as protein, DNA, and dsRNA are reduced to trace levels to minimize potential immunogenicity. Our comprehensive quality control panel rigorously verifies every critical attribute to ensure batch-to-batch consistency, ensuring data reproducibility in both in vitro and in vivo applications.